Benzinga | Nov 24, 2021 10:11AM EST

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $72

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $65 to $72.